EBGLYSS (Eli Lilly Australia Pty Ltd)
Product name
EBGLYSS
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
190 (255 working days)
Active ingredients
lebrikizumab
Registration type
NCE/NBE
Indication
EBGLYSS is indicated for the treatment of adult and adolescent patients (12 years of age and older) with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.